[Prevention of thrombosis with fraxiparin 0.3 after arthroscopic interventions].
METHODS
During a drug monitoring 101 men and women between 13 and 67 years underwent arthroscopic interventions on the knee on an outpatient basis and received the low-molecular-weight heparin, Fraxiparin 0.3, as prophylaxis of thromboembolism. In general the drug was administered the day before operation, two hours prior to operation and for five to six days postoperatively as a single daily s.c. dose.


RESULTS
During the period of treatment, one patient developed a deep venous thrombosis of the leg; on completion of observation time four more cases of venous thrombosis of the leg occurred. In contrast, no pulmonary embolisms were observed. Fraxiparin 0.3 has proved to be very well tolerated, undesired side effects did not occur, and in no case was the preventive treatment interrupted.
Holland
K
K
Ambulatorium für Arthroskopische Chirurgie, Hannover.
Schain
F H
FH
D000293:Adolescent; D000328:Adult; D000368:Aged; D001182:Arthroscopy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007719:Knee Joint / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017762:Nadroparin / Q000008:administration & dosage* / Q000009:adverse effects; D011183:Postoperative Complications / Q000517:prevention & control*; D011292:Premedication; D013923:Thromboembolism / Q000517:prevention & control*; D016896:Treatment Outcome
D017762:Nadroparin